Related Experiment Video
Updated: Oct 11, 2025
04:42
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
613
Long-term bumetanide administration altered behavioral pattern in mosaic Down's Syndrome: A case report
Zeinab Gharaylou1,2, Lida Shafaghi1, Seyed Khalil Pestehei3
1Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Applied Neuropsychology. Child
|December 3, 2021
Summary
This study explores how Gamma-aminobutyric acid (GABA) impacts cognitive deficits in Down's Syndrome (DS). Treatment with Bumetanide, an NKCC1 inhibitor, showed promise in improving behavioral deficits in a young boy with DS.
Area of Science:
- Neuroscience
- Genetics
- Developmental Biology
Background:
- Down's Syndrome (DS) is characterized by cognitive deficits affecting attention, executive functions, and communication.
- These deficits are linked to disruptions in neurotransmission and neuromodulation systems.
- Gamma-aminobutyric acid (GABA) plays a crucial role in neural regulation, and imbalances can exacerbate these issues.
Observation:
- The study focused on a fourteen-year-old boy with genetically confirmed mosaic Down's Syndrome.
- The individual exhibited significant behavioral deficits associated with cognitive impairments.
- The research investigated the potential of targeting GABAergic systems to address these deficits.
Findings:
- Bumetanide, a specific inhibitor of the NKCC1 co-transporter, was administered over an eighteen-month period.
- This intervention demonstrated promising effects in ameliorating some of the observed behavioral deficits.
- The results suggest a potential role for NKCC1 inhibition in managing Down's Syndrome-related behavioral issues.
Implications:
- Targeting NKCC1 and modulating GABAergic neurotransmission may offer a novel therapeutic strategy for Down's Syndrome.
- Further research is warranted to explore the efficacy and safety of Bumetanide in a broader DS population.
- These findings could lead to improved interventions for cognitive and behavioral challenges in individuals with Down's Syndrome.
